A weekly briefing on what changed this week across Branmoor’s 26 products — and what it means for the people who have to act on it.
What you will receive
- Drug shortages, recalls, and adverse events. New FDA drug shortages, status changes, recall classifications, and notable shifts in FAERS adverse-event volume — with the operational context a pharmacist or supply manager needs to read past the headline.
- Hospital and provider quality signals. Material moves in hospital-acquired infection rates, nursing home outcomes, ED throughput stress, dialysis center mortality, anesthesia/ASC safety signals, and surgical device failure patterns from the week’s primary-source data.
- Healthcare enforcement. New OIG exclusions, corporate integrity agreements, DOJ healthcare settlements, FCA unsealings, CMS survey deficiencies, and OCR breach notifications — tagged by rule, entity type, and compliance implication.
- Hospital financial and closure signals. Operating margin trajectory shifts, MSRB EMMA material events, and rural-hospital closure-risk updates from Medicare cost report and bond disclosure data.
- Payer, revenue-cycle, and rate signals. Payer policy and formulary changes, denial-rate disclosures, state rate-review filings, and contract-term updates — with the downstream revenue-cycle implications for managed-care and billing teams.
- Workforce, trial, and MA signals. Physician movements visible in NPPES, Medicare Advantage star-rating shifts, and new active clinical trial sites — the leading indicators recruiters, PE diligence teams, pharma, and CROs need.
- Data notes. Changes to the primary-source feeds themselves — new endpoints, schema revisions, methodology updates — that anyone working from this data should know about.
Who it is for
Pharmacists and pharmacy directors. Hospital supply chain and quality teams. Revenue-cycle and managed-care professionals. Healthcare compliance officers and counsel. Clinicians making formulary and substitution decisions. Healthcare investors, PE diligence teams, and lenders tracking portfolio company quality and financial signals. Researchers and journalists working in healthcare data. Anyone who benefits from primary-source data interpreted by people who read it every day.
What it is not
- Not medical advice. Not clinical guidance.
- Not advertising. We do not accept sponsorship from drug manufacturers, pharmacies, payers, or government agencies.
- Not a re-publisher. We do not forward press releases or repeat manufacturer statements without context.